Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Condition:   Plaque Psoriasis Interventions:   Biological: Adalimumab originator;   Biological: Adalimumab biosimilar Sponsor:   Alvotech Swiss AG Not yet recruiting

Source: ClinicalTrials.gov - July 1, 2020 Category: Research Source Type: clinical trials